NCT04252066 - A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

August 31, 2029

Study Completion Date

February 28, 2030

Conditions

Fabry Disease

Interventions

DRUG

migalastat

This is an observational study. Patients as described in Cohort 1 should have been exposed to at least 1 dose of migalastat during pregnancy and/or breastfeeding.

Trial Locations (1)

19104

RECRUITING

Amicus Therapeutics, Inc. Pregnancy Registry, Philadelphia